Active mobility early after stroke (AMOBES), 1 year follow-up. A randomised controlled trial
نویسندگان
چکیده
منابع مشابه
AMOBES (Active Mobility Very Early After Stroke)
In the early stage after stroke, within the first 2 weeks, physical therapy (PT) has 2 main goals: prevent immobilityrelated events and stimulate motor control recovery. However, the amount of PT to provide and the time after stroke for provision remain unclear. The organization of care in multidisciplinary stroke units has reduced the risk of death and dependency after stroke, with early mobil...
متن کاملTen year follow-up of a randomised controlled trial of care in a stroke rehabilitation unit.
Our quantitative findings indicate that a minority of professionals would recruit to a trial comparing planned caesarean section with planned vaginal birth. However, the qualitative finding—that midwives who favoured a trial did so because of their confidence in the benefits of vaginal birth—adds complexity because it negates the necessary individual professional equipoise. We explored the opin...
متن کاملFive year follow up of a randomised controlled trial of a stroke rehabilitation unit.
Caring for stroke patients in stroke units, compared with other hospital locations, leads to decreased mortality and disability at one year. A trial of a combined acute and rehabilitation ward in Trondheim, Norway, showed that hospital care improved survival and functional outcome at five years. The benefits were attributed to the treatment provided in the first few weeks after stroke. The purp...
متن کاملFamily support for stroke: one year follow up of a randomised controlled trial.
BACKGROUND There is evidence that family support can benefit carers of stroke patients, but not the patients themselves. OBJECTIVE To extend the follow up of a single blind randomised controlled trial of family support for stroke patients and carers to one year to ascertain whether there were any late effects of the intervention. METHODS The study was a randomised controlled trial. Patients...
متن کاملTreatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.
BACKGROUND Treatment with adjuvant trastuzumab for 1 year improves disease-free survival and overall survival in patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer. We aimed to assess disease-free survival and overall survival after a median follow-up of 4 years for patients enrolled on the Herceptin Adjuvant (HERA) trial. METHODS The HERA trial is an i...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Physical and Rehabilitation Medicine
سال: 2018
ISSN: 1877-0657
DOI: 10.1016/j.rehab.2018.05.044